Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects
- 1 March 1992
- journal article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 42 (3) , 347-348
- https://doi.org/10.1007/bf00266363
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotypeClinical Pharmacology & Therapeutics, 1991
- Debrisoquine oxidation phenotype during neuroleptic monotherapyEuropean Journal of Clinical Pharmacology, 1991
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine typeEuropean Journal of Clinical Pharmacology, 1990
- Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in luman beingsClinical Pharmacology & Therapeutics, 1989
- Substantial rise in sparteine metabolic ratio during haloperidol treatment.British Journal of Clinical Pharmacology, 1989
- Clinical significance of the sparteine/debrisoquine oxidation polymorphismEuropean Journal of Clinical Pharmacology, 1989
- Characterization of the common genetic defect in humans deficient in debrisoquine metabolismNature, 1988
- INHIBITORY EFFECTS OF NEUROLEPTICS ON DEBRISOQUINE OXIDATION IN MAN1986
- Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detectionJournal of Chromatography A, 1977